ノースカロライナにおける白血病の臨床試験
ノースカロライナ内の拠点で、白血病に関する20件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 27, Chapel Hill
被験者募集中第3相
18歳〜71歳 · 全性別 · 2026/09/23更新 · NCT07504458A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Duke University Medical Center, Durham
被験者募集中第1/2相
30 Days · 全性別 · 2026/09/16更新 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Novant Health Clinical Research, Charlotte
- East Carolina University, Greenville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06824168Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of North Carolina, Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Atrium Health Levine Cancer Center, Charlotte
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Levine Children's Hospital, Charlotte
被験者募集中第2相
7歳〜25歳 · 全性別 · 2026/08/19更新 · NCT05082519DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
被験者募集中
60歳以上 · 全性別 · 2026/08/14更新 · NCT06296368Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中健康なボランティア歓迎
6歳以上 · 全性別 · 2026/08/03更新 · NCT07634653Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
被験者募集中観察研究健康なボランティア歓迎
40歳〜49歳 · 全性別 · 2026/07/13更新 · NCT06870760Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
- Levine Cancer Institute, Charlotte
被験者募集中観察研究
18歳以上 · 全性別 · 2026/07/13更新 · NCT03555851Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- 他4件
被験者募集中観察研究
65歳以上 · 全性別 · 2026/06/29更新 · NCT01137825Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study of Revumenib and Mezigdomide in People With Leukemia
- University of North Carolina (Data Collection Only), Chapel Hill
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/06/22更新 · NCT07356154Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Duke Blood Cancer Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2025/10/27更新 · NCT01137643A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Durham VA Medical Center, Durham, NC, Durham
被験者募集中第2相
18歳〜80歳 · 全性別 · 2025/10/14更新 · NCT06520098ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。